Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | CCKBR | P32239 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750002 | 1.00 | CYP2D6 (0.70) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL6339966 | 1.00 | CYP2D6 (0.70) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5747498 | 1.00 | CYP2D6 (0.70) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5749582 | 1.00 | CYP2D6 (0.70) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5750858 | 1.00 | CYP2D6 (0.70) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL3481386 | 0.93 | CYP2D6 (0.81) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5746965 | 0.88 | CYP2D6 (0.66) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5748734 | 0.88 | CYP2D6 (0.66) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5751292 | 0.87 | CYP2D6 (0.65) | CYP2D6TSHRMAPK1CCKBRMEN1 | |
| SCHEMBL5750347 | 0.87 | CYP2D6 (0.65) | CYP2D6TSHRMAPK1CCKBRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438310-B1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | claimed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. | 2005-05-05 | — | — | US | disclosed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | CYP2D6 2426/4885TSHR 966/4885MAPK1 1157/4885 |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | CYP2D6 2426/4885TSHR 966/4885MAPK1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.